IMMIX BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested
IMMIX BIOPHARMA, INC. (IMMX) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested of $44.73 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested · last filed 2026-08-07
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for the quarter ending 2026-06-30 was $8.52M.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for the quarter ending 2026-03-31 was $36.21M.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for the quarter ending 2025-12-31 was $9.38M.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for the quarter ending 2025-09-30 was $57.51K.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for fiscal 2025 was $10.14M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $44.73M 10-Q · filed 2026-08-07 | $54.11M derived: sum of 3 quarters · filed 2026-08-07 | $54.17M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $36.21M 10-Q · filed 2026-05-07 | $45.59M derived: sum of 2 quarters · filed 2026-05-07 | $45.65M derived: sum of 3 quarters · filed 2026-05-07 | |
| 2025-12-31 | $9.38M derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-27 | $9.44M derived: sum of 2 quarters · filed 2026-03-27 | $10.14M 10-K/A · filed 2026-03-27 | |
| 2025-09-30 | $57.51K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $756.99K 10-Q · filed 2025-11-07 | ||
| 2025-06-30 | $699.48K 10-Q · filed 2025-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |